In the past decades, the inflammatory nature of atherosclerosis has been well-recognized and despite the development of therapeutic strategies targeted at its classical risk factors such as dyslipidemia and hypertension, atherosclerosis remains a major cause of morbidity and mortality. Additional strategies targeting the chronic inflammatory pathways underlying the development of atherosclerosis are therefore required. Interactions between different immune cells result in the secretion of inflammatory mediators, such as cytokines and chemokines, and fuel atherogenesis. Immune checkpoint proteins have a critical role in facilitating immune cell interactions and play an essential role in the development of atherosclerosis. Although the therapeutic potential of these molecules is wellrecognized in clinical oncology, the use of immune checkpoint modulators in atherosclerosis is still limited to experimental models. Here, we review recent insights on the role of immune checkpoint proteins in atherosclerosis. Additionally, we explore the therapeutic potential and challenges of immune checkpoint modulating strategies in cardiovascular medicine and we discuss novel therapeutic approaches to target these proteins in atherosclerosis.
Introduction
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVD), is a chronic, lipid driven, inflammatory disease of the arterial wall. 1 Despite the development of preventive strategies that target classical risk factors, such as hyperlipidemia and hypertension, atherosclerosis remains a major cause of morbidity and mortality. 2 Although most cardiovascular patients receive optimal medical and pharmaceutical care, a significant portion of these patients still suffers from recurrent cardiovascular events. 3 Additional therapeutic strategies targeted at the residual cardiovascular risk that exists even after best medical care are therefore required. Besides dyslipidemia, chronic low-grade inflammation determines the initiation and progression of atherosclerosis. 1 The therapeutic potential of strategies targeted at atherosclerosis-associated inflammation was recently highlighted by the CANTOS trial, in which antibody-mediated inhibition of IL-1b reduced the incidence of recurrent myocardial infarction, stroke, and cardiovascular death (HR: 0.85, 95% CI: 0.74-0.98) in patients with a previous myocardial infarction and high residual inflammatory risk. 4 The CANTOS trial confirmed the inflammatory hypothesis of atherosclerosis in humans and will therefore fuel the search for additional antiinflammatory strategies in atherosclerosis.
Immune checkpoint proteins have a central role in the regulation of inflammatory responses by facilitating the interaction between the various immune and non-immune cells, 5 and may either promote or hamper immune cell activation. Co-stimulatory molecules and co-inhibitory molecules are the most predominant members of the immune checkpoint protein family ( Figure 1A ). Immune checkpoint proteins are membrane proteins that are well-known for their role in T cell activation. Following initial T cell receptor-mediated activation, immune checkpoint proteins, which are expressed on antigen presenting cells (APCs) and T cells, provide the second signal that is vital for cellular activation ( Figure 1A) . 5 The third signal for T cell activation is provided by soluble factors, such as cytokines, which are also partially regulated by immune checkpoint proteins ( Figure 1A) . 5 Besides their classical role in T cell biology, immune checkpoint proteins also facilitate the interaction between immune cells and non-immune cells, such as endothelial cells, thereby orchestrating the secretion of cytokines and chemokines, survival, proliferation, and cellular polarization, which all shape the inflammatory response ( Figure 1B) .
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Because of their central role in the regulation of immune cells, modulation of immune checkpoints has the potential to limit inflammatory and malignant diseases, such as atherosclerosis and cancer. 6, 8 The great therapeutic potential of immune checkpoints has been emphasized by inhibitors have been implemented as therapy for various malignancies, including melanoma, lung carcinoma and haematological malignancies and numerous clinical trials focused on other types of cancer and other immune checkpoints are currently being conducted. 9, 10 In contrast to the major advances in clinical oncology, the modulation of immune checkpoints as a therapeutic strategy for CVD is still in its infancy. Although the results are promising, studies evaluating the therapeutic potential of immune checkpoints in CVD are limited to experimental models of atherosclerosis. Here, we will review the recent insights on the role of immune checkpoint proteins of the B7 immunoglobulin superfamily, including CD80/CD86-CD28/CTLA4 and PD-1-PD-L1/2, and the tumour necrosis factor receptor (TNFR) superfamily members CD27-CD70, CD137-CD137L, and CD40-CD40L in atherosclerosis ( Table 1) . In addition, we discuss the challenges of immune checkpoint targeting strategies in cardiovascular medicine and we explore novel therapeutic approaches to target immune checkpoints in CVD.
CD80/CD86-CD28/CTLA4
The CD80/CD86-CD28/CTLA4 pathway is the most extensively studied immune checkpoint. CD80 (B7.1) and CD86 (B7.2), which have an overlapping function, are mainly expressed on APCs. Both proteins are able to interact with the co-stimulatory protein CD28 on naïve and activated T cells, and the co-inhibitory molecule CTLA4, primarily expressed on activated T cells. Whereas activation of CD28 propagates immune responses by activating T cells and promoting survival and memory cell formation of both CD4 þ and CD8 þ T cells, CTLA4 limits T cell activation and induces regulatory T cell responses, thereby limiting inflammation and preventing autoimmunity. CTLA4, expressed on regulatory T cells, also regulates the expression of CD80/86 as it promotes trans-endocytosis-mediated down-regulation of these co-stimulatory proteins on APCs, thereby limiting the potential of these cells to induce CD4 þ T cell activation. [11] [12] [13] The importance of this suppressive mechanism is emphasized by patients with CTLA4 single nucleotide polymorphisms and CTLA4 haploinsufficiency, which exhibit decreased CTLA4 expression on regulatory T cells. [14] [15] [16] Consequently, regulatory T cells in these patients have an impaired ability to induce transendocytosismediated down-regulation of co-stimulatory molecules on APCs, 11, [14] [15] [16] thereby decreasing the in vitro suppressive capacity of regulatory T cells and inducing hyperactivation of effector T cells in vivo, resulting in lymphocytic infiltrates in the brain, gastro-intestinal tract, lymph nodes and lungs, amongst other organs. 11, 15, 16 These findings suggest that enhancing CTLA4-induced transendocytosis-mediated down-regulation of CD80/ 86 on APCs may improve inflammatory conditions. 17 In human and murine atherosclerosis, CD80 and CD86 are expressed on macrophages and T cells in both initial and advanced lesions. 18, 19 In patients with coronary artery disease (CAD), an increased expression of these proteins is observed in monocyte-derived dendritic cells (DCs), which may suggest increased DC-mediated co-stimulation of T cells in the human atherosclerotic plaque. 20 Both genetic deficiency and pharmacological inhibition of CD80/CD86, using the CTLA4-Ig fusion protein abatacept, reduced atherosclerotic burden in Ldlr -/-mice and in C57Bl/6J mice subjected to a model for post-interventional remodelling. 21, 22 The plaques in these mice contained fewer MHCII þ cells, smooth muscle cells, and less collagen, suggesting that CD80/86 inhibition halted the progression of initial atherosclerotic lesions to advanced lesions. 21 Although these observations were attributed to a favourable cytokine balance, i.e. decreased IFNc levels and increased IL-10 levels, the secretion of IFNc was only decreased after 8 weeks of high fat diet, but not after 20 weeks, suggesting that other factors, such as macrophage polarization, were involved as well. 21, 23 In contrast, Ldlr -/-mice reconstituted with Cd80/86 -/-bone marrow developed larger atherosclerotic lesions, due to a marked reduction in regulatory T cells numbers. 24 Abatacept treatment, which limits CD28-mediated activation of CD80/86, also reduced splenic regulatory T cell numbers in hypercholesterolemic mice. 22 In contrast to these animal studies, regulatory T cell numbers increased by 34% upon abatacept treatment in patients with rheumatoid arthritis (RA), possibly due to inhibition of CD95-mediated apoptosis. 25 However, the suppressive capacity of these regulatory T cells was reduced by 52.8%. 25 Accordingly, abatacept treatment failed to prevent allograft rejection in experimental models of transplantation. 26 Only limited data on the cardiovascular risk of abatacept users are available, but it has been reported that aortic stiffness was increased in 21 RA patients that used abatacept for 6 months. 27 These counterintuitive results may be explained by the fact that abatacept, in contrast to CTLA4, does not induce transendocytosis-mediated down-regulation of co-stimulatory molecules.
A B
Activation of the co-inhibitory CTLA4 is a promising alternative strategy as T cell specific over-expression of CTLA4 reduced atherosclerotic burden and plaque inflammation in Apoe -/-mice. 28 Although CTLA4
over-expression reduced splenic regulatory T cell numbers, the suppressive capacity of these cells was increased and effector T cells had a less inflammatory phenotype, which compensated for the reduced regulatory T cell numbers. 28 It would be interesting to investigate if CTLA4-mediated down-regulation of CD80/86 was affected in these transgenic mice. Although strategies that stimulate CTLA4 may impair anti-tumour responses, transgenic CTLA4 mice do not develop spontaneous tumours and abatacept does not increase the incidence of malignancies in patients with RA, suggesting that agonizing CTLA4 may be a safe approach in cardiovascular medicine. 29 Together these studies demonstrate that CD80/86-CD28 mediated co-stimulation promotes atherosclerosis by inducing Th1 responses, whereas CTLA4 limits plaque development by inducing antiinflammatory T cell responses. Therefore, pharmacological inhibition of CD80/86-CD28 or stimulation of CTLA4 are promising strategies for atherosclerosis.
PD-1-PD-L1/2
PD-1 is a co-inhibitory protein mainly expressed on T cells, but also on B cells, NKT cells and activated monocytes. PD-L1 and PD-L2 are expressed on a multitude of cell types, including macrophages, DCs, and non-haematopoietic cells, such as endothelial cells. 30 • Expressed on macrophages and T cells in human atherosclerotic plaques • Increased expression on monocyte-derived DC of CAD patients • Genetic or pharmacological inhibition ameliorates experimental atherosclerosis [18] [19] [20] [21] [22] CD80/86-CTLA4
• CTLA4 induces transendocytosis-mediated down-regulation of co-stimulatory molecules • CTLA4 over-expression enhances Treg-mediated suppression and reduces atherosclerosis [11] [12] [13] 28 PD-L1/2-PD-1
• Decreased expression on circulating T cells and myeloid DC of patients with CAD and ACS • PD-L1 is expressed on macrophages and DC in atherosclerotic plaques • PD-L1/2 deficiency induces an activated T cell phenotype • Genetic or pharmacological inhibition aggravates experimental atherosclerosis 33, 34, [36] [37] [38] Tumour necrosis factor receptor (TNFR) superfamily
CD70-CD27
• T cell proliferation. 30 ,31 PD-1-mediated suppression of the transcription factors GATA-3 and T-bet also limits effector T cell functions, such as Th1 cytokine production. 30, 31 Additionally, PD-L1, expressed on APCs, induces FoxP3 expression in naïve T cells, thereby promoting the development of regulatory T cells. 32 Observations in men and mice emphasize the importance of PD-1-induced T cell suppression. In humans, a single nucleotide polymorphisms that results in aberrant regulation of PD-1 has been associated with systemic lupus erythematosus and genetic deficiency of PD-1 in mice results in spontaneous auto-immune diseases, including arthritis and gastritis. 30, 33 PD-1 also plays a vital role in tumour immunity, and the therapeutic potential of PD-1-PD-L1/2 antagonizing strategies has been extensively studied in oncology, as discussed below.
In patients with an acute coronary syndrome or CAD, the expression of PD-1 and PD-L1 on circulating T cells and myeloid DCs is decreased. 34, 35 In Ldlr -/-mice, PD-L1 is detected on macrophages and DC within the atherosclerotic plaque and genetic deficiency of PD-L1/2 as well as antibody-mediated inhibition of PD-1 aggravated atherosclerosis. 36 Plaques were characterized by increased CD4 þ and CD8 þ T cell and macrophage numbers. SMC and collagen content were also increased, suggesting a more advanced plaque phenotype. 36 T cells in Pd-
-/-Ldlr -/-mice had an activated phenotype, characterized by high CD25 and low CD62L expression, and increased mRNA levels of proatherosclerotic cytokines such as IFNY, and TNFa. 37 Furthermore,
Pd-L1/2 -/-T cells were more susceptible to APC-mediated activation, which increased the levels of T cell-derived IL-2 and IFNc. 36 PD-1 deficiency increased regulatory T cell numbers in hyperlipidemic mice, but did not affect the suppressive capacity of these cells. 38 These results appear to conflict with the role of PD-L1 in regulatory T cell development, but may indicate that the overwhelming activation of CD4 þ and CD8 þ T cells in the Ldlr À/À Pd-1 À/À mice induced a reactive increase in regulatory T cell numbers and suggests that PD-1 has a redundant role in the development of these cells. Together, these pre-clinical data indicate that agonizing PD-1-PD-L1/2 strategies may ameliorate atherosclerosis by limiting detrimental T cell responses. Next, we will discuss the role of several promising TNFR superfamily members in atherosclerosis.
CD27-CD70
CD70 is expressed on activated T cells, B cells, macrophages, and DCs. Its receptor CD27 is found on naïve T cells, NK cells, B cells, and haematopoietic stem cells. Under homeostatic conditions CD70-CD27 interactions promote regulatory T cell development. During infection the dyad drives the immune response by promoting the expansion of antigen-primed T cells, memory cell formation and by inducing Th1 responses. 39 In human atherosclerosis, ruptured plaques display higher CD70 expression compared with stable lesions, with CD70 mainly detected on macrophages. 18, 39 CD27 is found on the majority of T cells in lesions, and reduced expression has been observed on peripheral blood mononuclear cells of patients with an acute myocardial infarction. 18 ,40 B cell restricted overexpression of CD70 increases effector T cells and Ly6C high monocyte numbers through CD27 activation on T cells. 41 Despite this inflammatory profile, these mice displayed reduced atherosclerotic burden, due to a depletion of splenic B cells, lower levels of oxLDL antibodies, increased apoptosis of monocytes, and slightly reduced cholesterol levels. 41 Both Apoe -/-Cd70 -/-mice and bone marrow specific Apoe -/-Cd70 -/-mice displayed increased atherosclerosis due to impaired macrophage viability and function. 39 Systemic or haematopoietic deficiency of CD27 also led to an increase in atherosclerotic burden. This was caused by a decrease in regulatory T cell numbers. Although their suppressive capacity was maintained, thymic regulatory T cells of Apoe -/-Cd27 -/-mice exhibited an increase in apoptosis and a decrease in proliferation, highlighting an important role for CD27-CD70 signalling in the development of these cells. 42 As such, these pre-clinical studies identified a complex role of the CD27-CD70 dyad in atherogenesis, but also suggest that agonistic CD27 or CD70 antibodies may reduce atherosclerosis. Interestingly, varlilumab, a human anti-CD27 monoclonal agonistic antibody, was recently shown to be effective in patients with advanced solid tumours. 43 In contrast to the observations in the atherosclerotic Cd27 -/-mice, varlilumab induced a strong decrease in regulatory T cell numbers and induced an activated CD4 þ T cell phenotype, characterized by increased expression of HLA-DR, CD69, CD137, and CD278, thereby promoting anti-tumour responses. Although this varlilumabinduced T cell profile may potentially aggravate atherosclerosis, no cardiovascular side effects were observed in this Phase I study. 43 Pre-clinical studies in mice and Phase I studies in cancer patients with advanced malignancies have resulted in potentially conflicting data on the role of the CD27-CD70 dyad in T cell biology, additional studies focused on the cell-type specific effects of CD27-CD70 signalling in atherosclerosis and the development of regulatory T cells are therefore required.
CD137-CD137L

CD8
þ T cells, and to a lesser extent CD4 þ T cells, are the main cell types expressing CD137 (Tumour necrosis factor receptor superfamily (TNFRSF 9)). Its ligand, CD137L (TNFSF 9), is mainly expressed on APCs. 44 Upon activation, other cell types, such as NK cells, granulocytes, eosinophils, mast cells, monocytes, and non-immune cells, can express these proteins as well. CD137-CD137L interactions induce T cell proliferation, augment cytotoxic T cell activities and induce cytokine secretion. 44 The dyad has a critical role in anti-tumour responses, such as tumour specific cytotoxic T cell responses and the formation of a tumour specific immunological memory. 45 Patients with ACS display increased levels of soluble and membranebound CD137 on circulating monocytes. 46, 47 Within the plaque, CD137
is present on EC and T cells, especially CD8 þ T cells, whereas CD137L
is predominantly expressed on macrophages. 48 Treatment of Apoe -/-mice with an agonistic CD137 antibody increased lesion size in initial atherosclerosis and increased the expression of cytokines, including IFNc, TNFa, IL-1b, MCP-1, and adhesion molecules, such as VCAM-1 and ICAM-1 within the plaque. [49] [50] [51] [52] Accordingly, Apoe -/-Cd137 -/-mice with advanced atherosclerotic lesions displayed a more stable plaque phenotype, characterized by a smaller necrotic core, increased collagen and SMC content and reduced MMP-9 expression, possibly due to a reduced frequency of IFNc producing T cells. 53 Although these data suggest that inhibition of the CD137-CD137L dyad may be beneficial for atherosclerosis, at least two issues require further attention. First, administration of CD137 blocking antibodies may have dual effects in inflammatory diseases. For example, antagonistic CD137L antibodies improved disease severity in experimental models of acute graft vs. host disease (GVHD) by reducing the cytotoxicity of CD8 þ T cells. 54 On the other hand, in chronic GVHD, anti-CD137L antibodies aggravated disease severity by enhancing CD4 þ T cell responses and inducing auto-antibody formation. 55, 56 Although the inflammatory response
Exploring immune checkpoints as potential therapeutic targets underlying GVHD differs from the inflammatory processes that promote atherosclerosis, both CD4 þ and CD8 þ T cells have critical roles in atherogenesis, 57 a detailed analysis of the effects of pharmacological inhibition of the CD137-CD137L dyad on these T cell subsets in mice with initial and advanced atherosclerosis is therefore necessary. Second, as CD137 acts as tumour suppressor in B cells, Cd137L -/-mice are prone to spontaneous B cell lymphomas. 58 Although no malignancies were observed in the atherosclerotic mice that were treated with antagonistic CD137 antibodies, careful evaluation of this potentially severe side effect is required before CD137-CD137L targeting strategies can be further developed towards an application in cardiovascular medicine. Interestingly, two agonistic anti-CD137 antibodies, urelumab and PF-05082566, are currently evaluated in clinical trials testing its effects on solid and haematological malignancies. 45, 59 In contrast to previous trials with urelumab, which were stopped due to severe liver toxicity and death in several patients, the more recent trials evaluate combinational approaches using agonistic CD137 antibodies and antibodies directed against tumour surface antigens, such as CD20 in lymphoma. In these combinations and at lower concentrations results look promising. In accordance with experimental atherosclerosis studies, short-term ex vivo treatment of human primary monocytes with agonistic CD137 antibodies induced increased TNF and IL-8 expression. 60 Although no cardiovascular side effects have been reported in these clinical studies so far, it will be important to carefully monitor if agonistic CD137 therapies aggravate CVD, especially because patients with manifest CVD were excluded from these initial trials.
CD40-CD40L
CD40 and its ligand CD40L (CD154) are expressed on immune cells, including B cells, T cells, DC, monocytes and macrophages, and nonimmune cells, including platelets, EC, adipocytes and SMC. 61 During atherogenesis, CD40 and CD40L are expressed on the majority of immune cells within the atherosclerotic plaque and circulation. 61 Genetic deficiency or antibody-mediated inhibition of CD40L reduced atherosclerosis in hypercholesterolemic mice by reducing the expression of adhesion molecules and chemokines, reducing the formation of platelet-leucocyte aggregates and limiting M1 and Th1 skewing of macrophages and T cells. In advanced atherosclerosis, CD40-activated macrophages secrete matrix metalloproteinases thereby contributing to plaque destabilization and rupture. Although these experimental studies identified the CD40-CD40L dyad as a promising therapeutic target for atherosclerosis, clinical trials evaluating anti-CD40L antibodies were halted due to thromboembolic events resulting from a disruption of CD40L-a IIb b3 integrin interactions in arterial thrombi. The alternative strategy to target the dyad, antibody-mediated inhibition of CD40, may result in immunosuppression and is therefore not feasible for the longterm treatment of chronic diseases such as atherosclerosis.
To further characterize the role of the CD40-CD40L dyad in atherosclerosis, the CD40 downstream signalling pathways important for atherosclerosis were explored. CD40 lacks intrinsic signalling activity and recruits tumour necrosis factor receptor associated factors (TRAFs) upon activation. The cytoplasmic tail of CD40 has a proximal TRAF6 and a distal TRAF2/3/5 binding site. Studies in mice with a deficiency in their CD40-TRAF interaction site in MHCII þ cells, revealed that CD40-TRAF6, and not CD40-TRAF2/3/5, have a critical role in atherosclerosis.
Cd40-traf6 -/-mice displayed reduced leucocyte recruitment to endothelium, reduced macrophage and T cell numbers in the plaque and limited M1 skewing (Figure 2) . 62 These data identified the CD40L-CD40-TRAF6 axis as potent anti-inflammatory target. To exploit its therapeutic potential, small molecule inhibitors of the CD40-TRAF6 interaction were developed and these successfully ameliorated several chronic inflammatory diseases, as discussed below. The co-inhibitory molecule TIGIT has multiple binding partners, including CD112, CD155, and CD226. 74 TIGIT inhibits T cell activation and proliferation. In hypercholesterolemic mice, TIGIT expression is upregulated on CD4 þ T cells. Although antibody-mediation activation of TIGIT limited pro-atherogenic T cell responses, it did not affect atherosclerotic burden in these animals, possibly due to increased DC activity. 74 Future studies should explore the role of the different TIGIT binding partners in atherosclerosis, as this may identify a more guided therapeutic approach.
Cardiovascular side effects of immune checkpoint inhibitors in clinical oncology
The therapeutic potential of immune checkpoints has been extensively studied in experimental and clinical oncology. The first two strategies that have been translated from bench to bedside are the antibody-mediated blockage of CTLA4 and the PD-1-PDL-1 dyad. CTLA4 inhibits T helper activities and promotes regulatory T cell functions, thereby dampening the initial phases of T cell activation. blockage of CTLA4 releases this brake, which results in activation of naive and memory T cells, increased T cell infiltration in tumours and limitation of regulatory T cell mediated suppression of effector T cells within the tumour microenvironment. In contrast to CTLA4, the PD-1-PD-L1 dyad regulates only the later phases of effector T cell activation, after homing from the circulation into the tissue or tumour microenvironment. Some tumours may express PD-1 and are therefore protected against T-cell mediated anti-tumour responses. Antibody-mediated blockage of PD-1-PD-L1 limits these suppressive effects and enhances the activity of effector T cells within the tumour microenvironment. Preclinical experiments also indicate that the combination of immune checkpoint inhibitors with other drugs may enhance efficacy. For example, a positive correlation between COX-2 expression and PD-L1 has been observed in both primary tumours and metastasis of melanoma and celecoxib-induced inhibition of COX-2 reduced PD-L1 expression in these malignancies and increased the susceptible for cytotoxic T cell responses, at least in vitro. 75 These pre-clinical data suggest that combinational approaches, for example combining COX-2 inhibitors and immune checkpoint inhibitors may further enhance anti-tumour responses. However, the currently available COX-2 inhibitors also impair the athero-protective effects of prostaglandin E2. 76 The potential of non-selective COX-2 blockers, such as aspirin, should therefore be evaluated. 77 Several antibodies have been approved by the food and drug administration (FDA) in the past years, including ipilimumab (anti-CTLA4), pembrolizumab and nivolumab (both anti-PD-1), and atezolizumab (anti-PD-L1). These antibodies improved the clinical outcome of patients with solid malignancies, including melanoma, metastatic lung cancer, kidney cancer, and bladder cancer, and in haematologic malignancies, such as Hodgkin lymphoma. The potency of these therapies is emphasized by the phenotype of Ctla4 -/-and Pd-1 -/-mice, which develop a lethal systemic immune hyperactivation syndrome, characterized by massive proliferation of lymphocytes and severe myocarditis and pancreatitis. 30, 78 In humans, antibody-mediated inhibition of co-inhibitory molecules may also result in side effects that resemble autoimmune disease, which are known as immune-related adverse effects. Although these immunerelated adverse effects can affect every organ, the skin, intestine, liver, and endocrine organs are most frequently involved, whereas involvement of the lungs, eyes, kidneys, pancreas, and brain is less common. The risk of immune-related adverse effects in a recent study was found to be 16.3% for PD-blockade, 27 .3% for CTLA4 blockade, and 55% for the combination therapy. 79 Furthermore, these adverse effects appear to be dose-dependent, at least for CTLA4 inhibiting agents. 80 Although these side effects are generally manageable, severe adverse effects can lead to withdrawal of treatment. [81] [82] [83] Cardiovascular side effects of immune checkpoint inhibitors, including myocarditis, cardiac fibrosis, myocardial fibrosis, cardiomyopathy, and heart failure, are rare with an incidence rate of 0.27%, but are often severe and fulminant cases have been reported in the past years. 81 Although the pathophysiological mechanism underlying these cardiac side effects is incompletely understood, 81, 84 post-mortem studies in two patients with lethal myocarditis upon ipilimumab and nivolumab treatment demonstrated the presence of leucocyte infiltrates, consisting of CD4 þ and CD8 þ T cells and macrophages in the myocardium and cardiac conduction system. 81, 85 These findings are in accordance with observations in Pd-1 -/-mice, which develop a lethal T-cell mediated myocarditis. 86 In contrast to the observations in the patients, humoral immune responses also contributed to the development of myocarditis in these mice, as auto-antibodies against cardiac troponin I were highly present. 30, 87 Besides these acute autoimmune-like cardiac side effects, inhibition of co-inhibitory pathways may aggravate chronic inflammatory diseases, such as atherosclerosis, by enhancing effector T cell responses and limiting regulatory T cell function in these diseases, especially when pre-clinical atherosclerosis is present in most of the patient that will receive immune checkpoint inhibitors. Immune checkpoint inhibitors have undoubtedly improved the clinical outcome in numerous cancers and although lethal cardiovascular toxicity of these agent is relatively rare, it is possible that the clinical Exploring immune checkpoints as potential therapeutic targets significance of these side effects has been under-estimated so far, as many clinical trials excluded patients with pre-existing CVD. And this problem may also emerge with new immune checkpoint inhibitors and combination treatments entering the clinics. 83, 88, 89 The recent launch of the multicenter ESC-Cardiac-Oncology Toxicity (COT) registry will enhance monitoring of the cardiovascular toxicity of immune checkpoint inhibitors in daily practice and may contribute to the development of evidence-based therapeutic strategies in the emerging field of cardiovascular-oncology. 83 
The challenges of immune checkpoint modulators in cardiovascular medicine
The success of immune checkpoint inhibitors in clinical oncology has highlighted the therapeutic potential of immune checkpoint proteins. However, extrapolation of these findings to the field of cardiovascular medicine is challenging. First, critical patient selection by applying the principles of personalized medicine is required. Patients with a high residual inflammatory cardiovascular risk, despite best medical care with conventional drugs, such as statins, anti-platelet therapies, and anti-hypertensive drugs, should be identified as these subjects will most likely benefit from immune checkpoint modulation. In the CANTOS trial, hsCRP was used as biomarker to identify subjects with a persisting inflammatory risk, 4 but novel biomarkers or imaging techniques could also be applied to select patient who will most likely benefit from immune checkpoint targeting strategies. Second, optimal timing and duration of immune checkpoint targeted strategies in cardiovascular medicine remains to be determined. Primary prevention commonly starts when atherosclerosis is already present in the patient, whereas secondary prevention is initiated after the occurrence of a cardiovascular event. Immune checkpoint modulators should therefore be able to induce either plaque regression or stabilization of rupture-prone plaques. Pre-clinical studies have demonstrated that the inhibition of co-stimulatory molecules, such as CD40-CD40L, indeed promotes plaque stabilization by increasing collagen content and limiting plaque inflammation. Although conventional therapies, including statins, may induce plaque stabilization, 90 it is currently unknown if immune checkpoint modulating strategies will have similar effects on human atherosclerosis. Third, antibody-mediated modulation of immune checkpoint proteins in cardiovascular medicine potentially results in severe immune suppression, especially because chronic inflammatory diseases may require longterm treatment. Although the incidence of these potential side effects is currently unknown, the CANTOS trial revealed that canakinumabmediated inhibition of IL-1b significantly increased the incidence rate of lethal infections (incidence rate, 0.31 vs. 0.18 events per 100 personyears; P = 0.02). As there may be redundancy between the various immune checkpoint regulators during severe infection, we can speculate that the incidence of these severe side effects may be lower upon immune checkpoint modulation as compared with IL-1b blockage. Additionally, screening for subclinical malignancies before the start of immune checkpoint modulators may be considered. In contrast to clinical oncology, these side effects are less tolerable in the setting of primary and secondary prevention of CVD. Alternative strategies to target immune checkpoint proteins in atherosclerosis may therefore be required.
Novel strategies to modulate immune checkpoints in atherosclerosis
Further investigation of the intracellular signalling pathways of costimulatory dyads relevant for atherosclerosis may identify novel therapeutic targets. One example is the CD40-TRAF6 interaction, as was discussed above. Small molecule mediated inhibition of the CD40-TRAF6 interaction improved insulin resistance in 3 models of dietinduced obesity and in diabetic db/db mice by limiting adipose tissue inflammation. 63, 64, 91 Moreover, it reduced neuroinflammation in experimental autoimmune encephalomyelitis by impairing monocyte recruitment to the central nervous system, improved survival in a model of polymicrobial sepsis and skewed monocytes towards an antiinflammatory phenotype in thioglycolate-induced peritonitis. [63] [64] [65] 92 These results suggest that small molecule mediated inhibition of the CD40-TRAF6 interaction may also improve atherosclerosis ( Figure 3A) . Importantly, the inhibitors did not result in immune suppression as the CD40-TRAF2/3/5 interaction, required for CD40-mediated immune responses, including immunoglobulin isotype switching, was intact.
Investigating downstream signalling pathways of other immune checkpoints will also result in the identification of new targets that have limited immune suppressive side effects. An alternative strategy to limit immune suppressive side effects of costimulation targeting strategies is cell-type specific inhibition of these dyads. For example, reconstituted HDL nanoparticles can be used to more specifically target myeloid cells, and not lymphoid cells, during atherosclerosis. Although immune checkpoint modulators have not yet been incorporated in these nanoparticles, HDL nanoparticles loaded with statins reduced plaque inflammation by targeting plaque macrophages in atherosclerotic mice 93 ( Figure 3B) . Also, in humans, liposomal nanoparticles have been used as carriers to deliver drugs to plaque macrophages. 94 These myeloid-specific nanoparticles or liposomes, loaded with compounds that inhibit the downstream signalling pathway of immune checkpoints, have the potential to reduce inflammation within the atherosclerotic plaque without affecting lymphoid cells, thereby preserving immunity. Peptide-drug conjugates could potentially also limit CVD. Ding and colleagues developed a CD40L specific peptide, A25, which was coupled to methotrexate-loaded liposomes. These A25-conjugated liposomes reduced CD40L þ cell numbers in vivo and ameliorated disease severity in experimental autoimmune encephalomyelitis by depleting pathogenic T cells. Similarly, the antibody-drug conjugate brentruximab vedotin, a conjugate of an anti-CD30 antibody and liposomes loaded with the chemotherapeutic agent monomethyl-auristatin-E, which targets CD30 þ cells in haematological malignancies is another example of this strategy ( Figure 3C ). Although conjugates of brentruximab and chemotherapeutic agents may not be feasible for the treatment of CVD, it demonstrates that antibody-drug conjugates have a great therapeutic potential and can be used to target immune checkpoint proteins, potentially also in the setting of CVD.
Conclusion
Immune checkpoint proteins orchestrate the chronic inflammation underlying atherosclerosis and many pre-clinical studies have highlighted the central role of these proteins in atherogenesis. Although antibody-mediated modulation of immune checkpoints successfully limits experimental atherosclerosis, translation of these results into the clinic is compromised by the risk of immunosuppression. Future studies should therefore focus on novel strategies to target immune checkpoints, including inhibition of the downstream signalling pathways used by these proteins and cell-type specific inhibition of immune checkpoints using nanoparticle technology and peptide-drug conjugates or antibody-drug conjugates. If these challenges can be addressed, modulation of immune checkpoints in CVD has the potential to successfully target the residual inflammatory risk that persists after treatment of classical cardiovascular risk factors. Exploring immune checkpoints as potential therapeutic targets
